Clinical application of molecular profiling in breast cancer

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Breast cancer is the leading type of cancer and second leading cause of cancer death in women. Breast cancer mortality has declined over the past 10 years largely due to early detection by mammographic screening, but also in part due to the increasing use of adjuvant hormonal therapy and chemotherapy. Indications for adjuvant chemotherapy have now expanded to include women who are at low risk of recurrence, resulting in overtreatment of most women to benefit a few, particularly those with favorable clinical features. New techniques have been evaluated that identify specific molecular signatures that may more accurately predict prognosis than clinical features, and that may also identify individuals who are more likely to benefit from endocrine therapy and/or chemotherapy. This review will focus on the clinical applications of these novel techniques reported to date, and how this may lead to the incorporation of molecular diagnostics into clinical practice. Two prospective, multicenter, multinational Phase III trials evaluating tumor genomic profiling in breast cancer are currently in development, and will be initiated within the forthcoming year. The completion of these important studies will represent the first step toward integrating molecular profiling into treatment selection for adjuvant therapy in breast cancer.

Original languageEnglish (US)
Pages (from-to)485-496
Number of pages12
JournalFuture Oncology
Volume1
Issue number4
DOIs
StatePublished - Aug 2005

Fingerprint

Breast Neoplasms
Drug Therapy
Second Primary Neoplasms
Molecular Pathology
Therapeutics
Adjuvant Chemotherapy
Cause of Death
Neoplasms
Recurrence
Mortality
Medical Overuse

Keywords

  • breast cancer
  • molecular profiling
  • predictive factors
  • prognostic factors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Clinical application of molecular profiling in breast cancer. / Sparano, Joseph A.; Fazzari, Melissa J.; Childs, Geoffrey J.

In: Future Oncology, Vol. 1, No. 4, 08.2005, p. 485-496.

Research output: Contribution to journalArticle

@article{483d46a9638842e4ada913c5ab2e220e,
title = "Clinical application of molecular profiling in breast cancer",
abstract = "Breast cancer is the leading type of cancer and second leading cause of cancer death in women. Breast cancer mortality has declined over the past 10 years largely due to early detection by mammographic screening, but also in part due to the increasing use of adjuvant hormonal therapy and chemotherapy. Indications for adjuvant chemotherapy have now expanded to include women who are at low risk of recurrence, resulting in overtreatment of most women to benefit a few, particularly those with favorable clinical features. New techniques have been evaluated that identify specific molecular signatures that may more accurately predict prognosis than clinical features, and that may also identify individuals who are more likely to benefit from endocrine therapy and/or chemotherapy. This review will focus on the clinical applications of these novel techniques reported to date, and how this may lead to the incorporation of molecular diagnostics into clinical practice. Two prospective, multicenter, multinational Phase III trials evaluating tumor genomic profiling in breast cancer are currently in development, and will be initiated within the forthcoming year. The completion of these important studies will represent the first step toward integrating molecular profiling into treatment selection for adjuvant therapy in breast cancer.",
keywords = "breast cancer, molecular profiling, predictive factors, prognostic factors",
author = "Sparano, {Joseph A.} and Fazzari, {Melissa J.} and Childs, {Geoffrey J.}",
year = "2005",
month = "8",
doi = "10.2217/14796694.1.4.485",
language = "English (US)",
volume = "1",
pages = "485--496",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Clinical application of molecular profiling in breast cancer

AU - Sparano, Joseph A.

AU - Fazzari, Melissa J.

AU - Childs, Geoffrey J.

PY - 2005/8

Y1 - 2005/8

N2 - Breast cancer is the leading type of cancer and second leading cause of cancer death in women. Breast cancer mortality has declined over the past 10 years largely due to early detection by mammographic screening, but also in part due to the increasing use of adjuvant hormonal therapy and chemotherapy. Indications for adjuvant chemotherapy have now expanded to include women who are at low risk of recurrence, resulting in overtreatment of most women to benefit a few, particularly those with favorable clinical features. New techniques have been evaluated that identify specific molecular signatures that may more accurately predict prognosis than clinical features, and that may also identify individuals who are more likely to benefit from endocrine therapy and/or chemotherapy. This review will focus on the clinical applications of these novel techniques reported to date, and how this may lead to the incorporation of molecular diagnostics into clinical practice. Two prospective, multicenter, multinational Phase III trials evaluating tumor genomic profiling in breast cancer are currently in development, and will be initiated within the forthcoming year. The completion of these important studies will represent the first step toward integrating molecular profiling into treatment selection for adjuvant therapy in breast cancer.

AB - Breast cancer is the leading type of cancer and second leading cause of cancer death in women. Breast cancer mortality has declined over the past 10 years largely due to early detection by mammographic screening, but also in part due to the increasing use of adjuvant hormonal therapy and chemotherapy. Indications for adjuvant chemotherapy have now expanded to include women who are at low risk of recurrence, resulting in overtreatment of most women to benefit a few, particularly those with favorable clinical features. New techniques have been evaluated that identify specific molecular signatures that may more accurately predict prognosis than clinical features, and that may also identify individuals who are more likely to benefit from endocrine therapy and/or chemotherapy. This review will focus on the clinical applications of these novel techniques reported to date, and how this may lead to the incorporation of molecular diagnostics into clinical practice. Two prospective, multicenter, multinational Phase III trials evaluating tumor genomic profiling in breast cancer are currently in development, and will be initiated within the forthcoming year. The completion of these important studies will represent the first step toward integrating molecular profiling into treatment selection for adjuvant therapy in breast cancer.

KW - breast cancer

KW - molecular profiling

KW - predictive factors

KW - prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=26444551734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26444551734&partnerID=8YFLogxK

U2 - 10.2217/14796694.1.4.485

DO - 10.2217/14796694.1.4.485

M3 - Article

VL - 1

SP - 485

EP - 496

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 4

ER -